argenx Discontinues Phase 3 UNITY Study in Sjögren’s Disease for Futility

The primary source directly states that argenx will discontinue the Phase 3 UNITY study after an interim analysis and an Independent Data Monitoring Committee recommendation to stop for futility because the study was unable to meet its primary endpoint. This is new, forward-looking clinical information with material implications for argenx’s Sjögren’s disease development and regulatory prospects, so it passes the development criteria and remains typed as clinical_study. Importance is high but limited primarily to argenx and the Sjögren’s pipeline; surprise is meaningful because the study had previously been described as ongoing with later topline results expected. The supplied 07:00Z timestamp was corrected to 05:00Z, which matches the source timestamp and the stated 7:00 AM Central European release time, although the source’s CET labeling creates some timezone uncertainty. ARGX is approved as the direct sponsor; IMVT and JNJ are also approved because the context explicitly identifies their FcRn programs in Sjögren’s disease, creating a credible mechanism- and indication-specific read-through. Other proposed stakeholders are excluded because their connection is broader, indirect, or insufficiently evidenced. The prior decision to create a new clinical-study event is retained because this is not a duplicate and the cited existing event concerns a separate Amgen program.